Ganaxolone

Small molecule

Approvedregulatory verdict

Evidence outlook

Approved: Epilepsy, Developmental and Epileptic Encephalopathies

Regulatory approval supersedes design-level evidence grading; the trials behind approval are preserved below as the drug's evidence history.

track record: Partial signal

Also approved (1)
EU
  • Ztalmy is indicated for the adjunctive treatment of epileptic seizures associated with cyclin-dependent kinase-like 5 (CDKL5) deficiency disorder (CDD) in patients 2 to 17 years of age. Ztalmy may be continued in patients 18 years of age and older.
Product first approved 2023EMA

How the evidence outlook works ↗

All registered studies

Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase.

Phase 3 (8)
Epilepsy
NCT05604170 · Marinus Pharmaceuticals
2022-05-16 – 2025-04-02 · Tuberous Sclerosis Complex
What this study did
NCT05323734 · Marinus Pharmaceuticals
2022-04-01 – 2024-10-14 · Tuberous Sclerosis Complex
What this study did
NCT05814523 · Marinus Pharmaceuticals
2024-03 – 2024-08 · Refractory Status Epilepticus
What this study did
NCT02519439 · Marinus Pharmaceuticals
2015-02 – 2016-12 · Drug Resistant Partial Onset Seizure
What this study did
Other / comorbidity
NCT05249556 · Immedica Pharma AB
2027-03 – 2029-12 · CDKL5 Deficiency Disorder
What this study did
Phase 2 (16)
Epilepsy
NCT05757544 · Marinus Pharmaceuticals
2023-04-01 – 2026-02 · Status Epilepticus
What this study did
NCT03865732 · Marinus Pharmaceuticals
2019-05-17 – 2022-06-20 · PCDH19-Related Epilepsy
What this study did
NCT03350035 · Marinus Pharmaceuticals
2018-02-19 – 2019-09-18 · Status Epilepticus, Convulsive Status EPILEPTICUS, Non Convulsive Status Epilepticus, Epilepsy
What this study did
NCT02358538 · Marinus Pharmaceuticals
2015-11-06 – 2019-01-04 · Epilepsy
What this study did
NCT00512317 · Marinus Pharmaceuticals
2007-06 – 2013-09 · Epilepsies, Partial
What this study did
NCT01002820 · Marinus Pharmaceuticals
2009-10 – 2013-08 · Epilepsy, Complex Partial
What this study did
NCT00442104 · Marinus Pharmaceuticals
2007-01 – 2009-03 · Infantile Spasms
What this study did
NCT00465517 · Marinus Pharmaceuticals
2007-02 – 2008-11 · Partial Epilepsy, Catamenial Epilepsy
What this study did
NCT00441896 · Marinus Pharmaceuticals
2007-01 – 2008-05 · Infantile Spasms
What this study did
Other / comorbidity
NCT07635862 · Stanford University
2027-01-01 – 2030-01-01 · Autism in Children, Autistic Disorder in Children and Adolescents, Autism Spectrum Disorder
What this study did
NCT04285346 · Marinus Pharmaceuticals
2020-04-08 – 2022-08-30 · Tuberous Sclerosis
What this study did
NCT03228394 · Marinus Pharmaceuticals
2017-06-27 – 2020-05-10 · Depression, Depressive Disorder, Depression, Postpartum, Behavioral Symptoms, Mood Disorders, Mental Disorders, Puerperal Disorders, Pregnancy Complications, Postpartum, PPD
What this study did
NCT03460756 · Marinus Pharmaceuticals
2017-12-28 – 2019-07-05 · Depressive Disorder, Depression, Depression, Postpartum, Behavioral Symptoms, Mood Disorders, Mental Disorder, Pregnancy Complications, Postpartum Blues, PPD, Postpartum Disorder
What this study did
NCT01725152 · Marinus Pharmaceuticals
2012-11 – 2016-11-01 · Fragile x Syndrome
What this study did
NCT01339689 · Marinus Pharmaceuticals
2011-04 – 2014-03 · PTSD
What this study did
NCT01857531 · Jed E. Rose
2013-06 – 2014-02 · Smoking Cessation
What this study did
Early phase / not applicable (1)
Other / comorbidity
NCT02900092 · Massachusetts General Hospital
2016-11 – 2018-01-12 · Major Depressive Disorder
What this study did

Competitive landscape

This mechanism is crowded: 14 other tracked programmes target it, none of them ahead of this one.

This drug's own stage for Developmental and Epileptic Encephalopathies: Approved. Competitors below are sorted furthest-along first.

DrugStageModalityMechanismEvidence signalReported efficacygraded featured trials
Ganaxolone: this drugApprovedSmall moleculeGABA-A receptorPartial signal
NCT03572933: Median percentage change in 28-day major motor seizure frequency: ganaxolone -30.7% vs placebo -6.9% (p=0.0036); Hodges-Lehmann median difference -27.1% (95% CI -47.9 to -9.6), n=100 (Knight et al., Lancet Neurol 2022).
Cannabidiol (Epidiolex)ApprovedSmall moleculeGPR55 / TRPV1 / adenosine transport (multi-target), cannabinoidReliable signal
NCT02091375: Percentage Change From Baseline In Convulsive Seizure Frequency During The Treatment Period (Baseline to End of Treatment (EOT) (Day 99) or Early Termination (ET)): GWP42003-P 20 mg/kg/Day Dose -38.94 percent change (IQR -69.53 to -4.83) vs Placebo -13.29 percent change (IQR -52.53 to 20.2)
Clobazam (Onfi)ApprovedSmall moleculeGABA-A receptorReliable signal
NCT00518713: Percent Reduction in Number of Drop Seizures (12-week Maintenance Period). (4-week baseline period and 12-week maintenance period): Clobazam Low Dose 41.2 Percent Reduction (range -119 to 100) | Clobazam Medium Dose 49.4 Percent Reduction (range -262 to 100) | Clobazam High Dose 68.3 Percent Reduction (range -39 to 100) vs Placebo 12.1 Percent Reduction (range -374 to 100)
Clobazam (Sympazan)ApprovedSmall moleculeGABA-A receptor (benzodiazepine site)not yet gradedNo reviewed efficacy summary in this indication
Fenfluramine (Fintepla)ApprovedSmall moleculeSerotonin 5-HT2 receptorsReliable signal
NCT03355209: Percentage change from baseline in drop-seizure frequency, fenfluramine 0.7 mg/kg/day (n=87) vs placebo (n=87): median reduction 26.5 vs 7.6 percentage points; estimated median difference -19.9 percentage points (95% CI -31.0 to -8.7; P=.001).
NCT02682927: Change From Baseline in the Mean Convulsive Seizures Frequency (MCSF) to the Combined Titration and Maintenance Periods (T+M) in Participants Receiving ZX008 0.8 mg/kg/Day Compared to Placebo (From Baseline up to 14 weeks [Titration Period (2 weeks) plus Maintenance Period (12 weeks)]): Study 1: ZX008 0.8 mg/kg/Day -13.11 seizure frequency per 28 days (Standard Deviation 25.5) | Study 3: ZX008 0.8 mg/kg/Day -3.54 seizure frequency per 28 days (Standard Deviation 124.132) vs Study 1: Placebo -6.71 seizure frequency per 28 days (Standard Deviation 24.263) | Study 3: Placebo 1.54 seizure frequency per 28 days (Standard Deviation 21.966)
RufinamideApprovedSmall moleculeVoltage-gated sodium channelnot yet gradedNo reviewed efficacy summary in this indication
StiripentolApprovedSmall moleculeGABA-A receptorWeak signalNo reviewed efficacy summary in this indication
Vigabatrin (Sabril)ApprovedSmall moleculeGABA transaminase (GABA-T)not yet gradedNo reviewed efficacy summary in this indication
Vigabatrin (Vigafyde)ApprovedSmall moleculeGABA transaminase (GABA-T)not yet gradedNo reviewed efficacy summary in this indication
KH607
Phase 3(overall)
Small moleculeGABA-A receptor
Partial signal(overall)
No reviewed efficacy summary in this indication
RelutriginePhase 3Small moleculeVoltage-gated sodium channel (persistent current)not yet gradedNo reviewed efficacy summary in this indication
BMB-101Phase 2Small moleculeSerotonin 5-HT2C receptor (biased agonist)not yet gradedNo reviewed efficacy summary in this indication
GlyphAllo (allopregnanolone Prodrug) (SPT-300)
Phase 2(overall)
Small moleculeGABA-A receptor
not yet graded(overall)
No reviewed efficacy summary in this indication
HS-10353
Phase 2(overall)
Small moleculeGABA-A receptor
Partial signal(overall)
No reviewed efficacy summary in this indication
Remimazolam
Phase 1(overall)
Small moleculeGABA-A receptor
not yet graded(overall)
No reviewed efficacy summary in this indication

Compare side by side

4 further pairs are tracked; the rosters on each shared mechanism and indication page list every rival in the race.

Upcoming events

(2 total)

Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Follow Ganaxolone to get an email as a readout nears, when a date moves, or when a study changes status. Needs a free account.

Add these readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2029 (1)
December 2029 (1)
Phase 3CDKL5 Deficiency DisorderNot yet recruiting
Est. primary completion 2029-12 · NCT05249556 · CT.gov ↗
What to watch
2030 (1)
January 2030 (1)
Phase 2Autism in Children, Autistic Disorder in Children and Adolescents, Autism Spectrum DisorderNot yet recruiting
Est. primary completion 2030-01-01 · NCT07635862 · CT.gov ↗
What to watch

See the full readout calendar ↗